Investment Rating - Investment rating is maintained as "Buy" [1] Core Views - The company announced an updated shareholder return policy, increasing the cash dividend ratio to "not less than 30% of the net profit attributable to shareholders" for the next three years, reflecting a commitment to enhancing investor returns and attracting long-term capital [5] - The demand for phosphate fertilizers is expected to remain strong due to tight upstream supply and increasing downstream demand during the spring farming season, supporting high price levels [6] - The company’s core products include diammonium phosphate, urea, and polyvinyl chloride (PVC), with urea prices currently at a low point, but expected to rebound as the spring farming season begins [7] Summary by Sections Shareholder Returns - The company plans to increase cash dividends significantly compared to previous years, aiming for a total cash dividend amount that is at least 30% of the annual net profit attributable to shareholders, and a cumulative amount over three years that is not less than 35% of the average annual net profit [5] Market Conditions - The upstream supply of phosphate rock and sulfur remains tight, with sulfur prices in February 2025 showing a year-on-year increase of 69.6%, which supports phosphate prices [6] - International market prices for diammonium phosphate are also rising, with a February 2025 price of $625.2 per ton, reflecting a year-on-year increase of 5.6% [6] Financial Projections - The company’s projected net profits for 2024, 2025, and 2026 are 1.088 billion, 1.186 billion, and 1.381 billion yuan respectively, with year-on-year growth rates of 140.1%, 9.0%, and 16.4% [9] - The expected price-to-earnings ratios for these years are 12, 11, and 10 times respectively, indicating a favorable valuation outlook [9] Operational Insights - The company’s new coal mining operations in Xinjiang, with an annual capacity of 30 million tons, will enhance its supply chain and provide stable raw material sources for its chemical production [8] - PVC prices are currently at a low point, but the company’s production method allows for cost-effective production, which will help maintain stable operations despite market pressures [8]

Investment Rating - The investment rating for the company is "Buy" (maintained) [2] Core Insights - The report indicates that the profitability recovery process of the company has exceeded expectations, with a confirmed turning point in Q4 2024 [7][9] - The company reported Q4 revenue of 1.132 billion yuan (down 0.22% year-on-year) and a net profit attributable to shareholders of 162 million yuan (up 372.40% year-on-year) [9] - The report highlights improvements in both domestic and international sales, with Q4 domestic sales experiencing a slight decline and international sales showing low double-digit growth [9] Financial Performance Summary - Q4 2024: Revenue of 1.132 billion yuan, net profit of 162 million yuan, and a net profit margin of 14.3%, marking a significant increase from previous quarters [9] - For the full year 2024, the company reported revenue of 3.414 billion yuan (down 4.02% year-on-year) and a net profit of 122 million yuan (up 1.14% year-on-year) [9] - The report projects revenue growth for 2025 and 2026, with expected revenues of 4.114 billion yuan and 4.813 billion yuan, respectively, indicating a recovery trajectory [11] Revenue and Profit Analysis - Q4 revenue growth improved compared to Q3, with domestic sales benefiting from promotional activities and a recovery in market share [9] - The gross margin for Q4 is expected to reach 35%, up from 28% in Q3, driven by cost reductions and an improved product mix [9] - The report emphasizes the potential for growth in the 2B segment, particularly in the automotive and commercial sectors [9] Earnings Forecast - The earnings forecast has been adjusted based on the positive Q4 performance, with projected net profits of 1.22 billion yuan for 2024, 4.01 billion yuan for 2025, and 5.56 billion yuan for 2026 [9][11] - The report maintains a price-to-earnings ratio (P/E) of 73 for 2024, 22 for 2025, and 16 for 2026, reflecting the anticipated recovery and growth [9]

证券研究报告 2025年2月24日 分析师：郑小霞 SAC执业证书号：S0010520080007 联系方式：zhengxx@hazq.com 分析师：张运智 SAC执业证书号：S0010523070001 联系方式：zhangyz@hazq.com 加征关税风险暂缓，关注国内政策应对 — 大 类 资 产 配 置 月 报 第 4 4 期 ： 2 0 2 5 年 3 月 1 核心结论：加征关税风险暂缓，关注国内政策应对 | 大类 | 项目 | | | 本期：2025-2-24至2025-3-28 | 上期：2025-1-24至2025-2-24 | | | --- | --- | --- | --- | --- | --- | --- | | | | 投资建议 | 较上期变化 | 核心观点与逻辑支撑 | 指数变动 | 涨跌 | | 股指 | 上证指数 | 震荡 | → | 市场对"两会"政策的预期将回归现实，经济基本面边际变 | 3252.63-->3379.11 | 3.89% | | | 创业板指 | 震荡 | ↓ | 化微弱，海外风险扰动有限，市场预计小幅波动。 | 2121.84-->2281.51 | ...

证券研究报告 AIDC电源报告：算力浪潮起，电源擎动AIDC 敬请参阅末页重要声明及评级说明 2 1. 人工智能快速发展，AIDC基石迎高速建设期 2. 推理业务负载占比提升，AIDC对供电设备要求升级 3. AIDC推动电力设备容量升级，关注量增、价增环节 4. 投资建议与产业链相关公司梳理 5. 风险提示 分析师：张志邦(S0010523120004) 分析师：郑洋（S0010524110003） 2025 年 2 月23 日 证券研究报告 华安证券研究所 华安研究 •拓展投资价值 证券研究报告 华安研究•拓展投资价值 目录： 华安证券研究所 1. 人工智能快速发展，AIDC基石迎高速建设期 华安证券研究所 敬请参阅末页重要声明及评级说明 3 证券研究报告 华安研究 •拓展投资价值 1.人工智能快速发展，AIDC基石迎高速建设期 • 通算中心向智算中心升级，全球AI市场有望实现高速增长。通算中心主要以云计算为主，随着生成式人工智能(AIGC ）的出现，通算中心（传统数据中心）已逐渐无法满足日益增长的计算需求，智算中心（AIDC）应运而生，支持大 规模的数据处理等智能算法需求。各国争相布局智算市场，中国云计 ...

Investment Rating - Investment Rating: Buy (Maintained) [2] Core Views - The company achieved revenue of 77.34 billion yuan in Q4 2024, representing a year-over-year increase of 21.8%. Adjusted net profit was 4.52 billion yuan, up 181.4% year-over-year, with growth potential driven by AI in gaming and advertising [5][6] - The game "Three Kingdoms: Strategy" has demonstrated long-term operational capabilities, supporting sustained growth in the gaming business. The global market for SLG games is estimated at 70 billion yuan, with an average game lifespan exceeding 5 years [6] - Advertising business continues to grow rapidly, supported by core user growth. Daily active users (DAU) reached 103 million, up 2.9% year-over-year, while monthly active users (MAU) reached 340 million. The average daily usage time increased by 4.2% to 99 minutes, with daily video views exceeding 4.8 billion [7] Financial Summary - For 2025, 2026, and 2027, the company is expected to achieve revenues of 306.6 billion yuan, 336.2 billion yuan, and 359.6 billion yuan, respectively. Adjusted net profits are projected at 18.8 billion yuan, 33.2 billion yuan, and 40.4 billion yuan for the same years [5][9] - Key financial indicators for 2024A include total revenue of 26,832 million yuan, with a year-over-year growth of 19%. Adjusted net profit is forecasted to be -39 million yuan, with a significant recovery expected in subsequent years [9][10] - The company’s cash flow from operating activities is projected to turn positive in 2025, with net profit expected to reach 811 million yuan [11]

赵老师 e_IndNameRptType] 电力设备 行业周报 Figure AI 公布新模型，机器人及 AIDC 有望受益 [Table_IndRank] 行业评级：增持 报告日期： 2025-02-24 [Table_Chart] 行业指数与沪深 300 走势比较 -22% -9% 4% 16% 29% 42% 2/24 5/24 8/24 11/24 电力设备 沪深300 [Table_Author] 分析师：张志邦 执业证书号：S0010523120004 邮箱：zhangzhibang@hazq.com 分析师：刘千琳 执业证书号：S0010524050002 邮箱：liuqianlin@hazq.com 主要观点： 光伏：本周产业链价格持平；BC 进展受市场关注，如铜浆、铜粉在下游组件大厂 的验证情况较好，带动相关标的表现；我们判断 Q2 或将受益于基本面修复和政策 预期的逐渐落地，接近板块右侧启动期。 风电：海风右侧已至，关注塔筒桩基环节。2024 年 1-12 月，国内风电装机 79GW， 同比+5%，其中 12 月新增装机 27.6GW，环比+364%。海风项目开工超预期刺激板块 情绪，市场 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company is expected to achieve a net profit of 9.24 billion yuan in 2024, marking a significant turnaround from losses in previous years [2] - Revenue for 2024 is projected to be 104.9 billion yuan, reflecting a year-on-year growth of 16.7% [2] - The comprehensive cost of raising pigs is expected to decrease to 14 yuan per kilogram in Q4 2024, with a significant improvement in core production indicators [2] - The company plans to increase its pig sales target for 2025 to between 33 million and 35 million heads, supported by a stable breeding stock [2] - The chicken output for 2024 is projected at 1.208 billion birds, with a target growth of over 5% for 2025 [4] Financial Summary - The company forecasts net profits of 9.25 billion yuan, 12.35 billion yuan, and 11.18 billion yuan for 2024, 2025, and 2026 respectively, with year-on-year growth rates of 244.9%, 33.4%, and -9.4% [7] - The expected revenue for 2024 is 105.17 billion yuan, with a year-on-year increase of 17% [9] - The gross profit margin is projected to be 17% in 2024, with a return on equity (ROE) of 22.7% [9] - The earnings per share (EPS) are expected to be 1.39 yuan in 2024, increasing to 1.86 yuan in 2025 [9]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company is expected to achieve a net profit of 9.24 billion yuan in 2024, marking a significant turnaround from losses in previous years. Revenue is projected to reach 104.9 billion yuan, reflecting a year-on-year growth of 16.7% [2] - The core production metrics are continuously improving, with the comprehensive cost of raising pigs dropping to 14 yuan per kilogram in Q4 2024. The company plans to increase its pig sales target for 2025 to between 33 million and 35 million heads [2][3] - The company has also seen a steady increase in chicken output, with a total of 1.208 billion chickens raised in 2024, a 2.1% increase year-on-year. The comprehensive cost of chicken production decreased to 11.4 yuan per kilogram in Q4 2024 [3][4] Financial Summary - The company forecasts pig output of 30.18 million heads in 2024, increasing to 34 million heads in 2025 and 37 million heads in 2026. Chicken output is expected to rise from 1.208 billion in 2024 to 1.332 billion in 2026. Corresponding net profits are projected at 9.255 billion yuan for 2024, 12.349 billion yuan for 2025, and 11.183 billion yuan for 2026, with year-on-year growth rates of 244.9%, 33.4%, and -9.4% respectively [7] - The company's revenue is expected to grow from 89.921 billion yuan in 2023 to 105.169 billion yuan in 2024, with a year-on-year growth of 17%. The gross profit margin is projected to improve to 17% in 2024 [9]

Investment Rating - Investment Rating: Buy (Maintained) [2] Core Views - The company achieved revenue of 77.34 billion yuan in Q4 2024, representing a year-over-year increase of 21.8%. Adjusted net profit was 4.52 billion yuan, up 181.4% year-over-year, with growth potential driven by AI in gaming and advertising [5] - The long-term operational capability of the game "Three Kingdoms: Strategy" has been preliminarily validated, supporting sustained growth in the gaming business. The global market for SLG games is estimated at 70 billion yuan, with an average game lifespan exceeding 5 years [6] - Advertising business continues to show high growth, supported by core user growth. The company reported a DAU of 103 million, up 2.9% year-over-year, and a MAU of 340 million. Daily average usage time increased by 4.2% to 99 minutes, with daily video views exceeding 4.8 billion [7] - Revenue projections for 2025, 2026, and 2027 are 306.6 billion yuan, 336.2 billion yuan, and 359.6 billion yuan respectively, with adjusted net profits of 18.8 billion yuan, 33.2 billion yuan, and 40.4 billion yuan [7] Financial Summary - Total revenue for 2024 is projected at 26,832 million yuan, with a growth rate of 19%. Adjusted net profit is expected to be 1,878 million yuan in 2025, a significant increase from a loss of 39 million yuan in 2024 [9] - The company is expected to achieve an EPS (NON-GAAP) of 4.46 yuan in 2025, with a P/E ratio of 37.32 [10] - The gross margin is projected to improve from 32.7% in 2024 to 39.1% by 2026, indicating enhanced profitability [11]

Investment Rating - The report indicates a strong growth potential in the gene sequencing industry, with an expected market size exceeding 150 billion yuan by 2030, highlighting it as one of the fastest-growing sectors in in vitro diagnostics [30]. Core Insights - The gene sequencing market in China is projected to grow from 72 billion yuan in 2016 to 374 billion yuan by 2024, with a compound annual growth rate (CAGR) of 25.8% expected from 2025 to 2030 [30]. - The report emphasizes the transition from traditional sequencing methods to advanced fourth-generation sequencing technologies, which offer unique advantages such as ultra-long reads and real-time monitoring [4][20]. - The integration of AI models in processing and analyzing vast amounts of genetic data is identified as a key competitive advantage for companies in the industry [32]. Summary by Sections Gene Sequencing Definition and Classification - Gene sequencing is defined as a molecular biology technique used to determine the nucleotide sequence of DNA molecules, crucial for various fields including genetic disease diagnosis and personalized medicine [13][10]. - The classification of gene sequencing includes first, second, third, and fourth-generation technologies, with the fourth generation being the most advanced [11][17]. Development History and Characteristics of Gene Sequencing - The report outlines the evolution of gene sequencing technologies, highlighting the limitations of earlier methods and the advancements made in high-throughput sequencing [17]. - The cost of gene sequencing has significantly decreased, following Moore's Law, with the cost of whole genome sequencing dropping from 1 million USD in 2007 to under 100 USD in 2024 [19]. Market Size and Competitive Landscape - The gene sequencing market is expected to exceed 150 billion yuan by 2030, driven by its applications in clinical medicine and drug development [30]. - The report identifies key players in the market, including Illumina, Oxford Nanopore Technologies, and BGI, each with unique technological advantages and market strategies [43][46][48]. Key Companies in Gene Sequencing - Illumina is recognized as a leader in the gene sequencing technology space, known for its high-throughput sequencing systems that are widely used in genomics research [43]. - Oxford Nanopore Technologies specializes in fourth-generation sequencing technology, offering portable and flexible sequencing solutions [46]. - BGI is noted for its comprehensive capabilities in high-throughput sequencing and its recent legal victories that enhance its market position [48]. - Other notable companies include Berry Genomics, Dian Diagnostics, and Novogene, each contributing to advancements in gene sequencing and AI applications in clinical settings [49][52][54].